RESUMO
Objective:To investigate the clinical characteristics and prognosis of acute myeloid leukemia (AML) patients with positive TLS-ERG fusion gene.Methods:The clinical data of 9 AML patients with positive TLS-ERG fusion gene in the First Hospital of Jilin University from June 2013 to August 2020 were retrospectively analyzed, and the relevant literature was reviewed.Results:Among 9 patients with positive TLS-ERG fusion gene, there were 5 males and 4 females, with a median age of 16 years old (6-40 years old). Five patients received chemotherapy alone, 3 patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT), and 1 patient did not receive systematic treatment. Among 8 patients with systematic treatment, 1 patient had complete remission after the first induction chemotherapy and 5 patients had complete remission after induction therapy. The median overall survival time of 5 patients with chemotherapy alone was 1.5 months (1-11 months), of which 3 patients did not respond to the first course of treatment and died of infection, and 2 patients died after relapse. The median overall survival time of 3 patients with allo-HSCT was 16 months (13-17 months), of which 2 patients died after relapse and 1 patient had sustained molecular complete remission by the end of follow-up.Conclusions:AML with positive TLS-ERG fusion gene has low incidence rate and poor induction efficacy. Hematopoietic stem cell transplantation may partially improve the survival prognosis of patients, but it cannot overcome the adverse effect of positive TLS-ERG fusion gene on prognosis.
RESUMO
Objective@#To investigate the clinical characteristics and prognosis of adult acute myeloid leukemia (AML) with TLS-ERG fusion gene positive.@*Methods@#Adult two AML patients with TLS-ERG fusion gene positive in the First Affiliated Hospital of Zhengzhou University in January 2017 and March 2018, respectively were enrolled, and their clinical characteristics and prognosis were analyzed.@*Results@#Both patients with TLS-ERG fusion gene positive were males. According to morphology classification, the first case was classified to AML-M5, and the other one was AML-M4. Both patients' immunophenotypic features showed CD56 expression, and CD25 was expressed in the first patient simultaneously. Both patients were treated with induction and consolidated intensive therapy based on Chinese guidelines for diagnosis and treatment of adult AML (not acute promyelocytic leukemia) and the guidelines for diagnosis and treatment of AML (relapse/refractory) in China. The first patient died 11 months after diagnosis, and the second patient remained in remission until the end of follow-up in February 2019 (12 months after diagnosis).@*Conclusion@#TLS-ERG fusion gene has low incidence rate, high recurrence rate, poor reinduction effect, poor prognosis and short survival time in adult AML.